Neuroprotection

This fully revised edition explores the management of neurological disorders with a focus on neuroprotection, disease modification, and neuroregeneration rather than symptomatic treatment. Since the publication of the first edition, advances in biotechnology, particularly in cell and gene therapies, are reflected in this volume, as are numerous new and repurposed drugs in clinical trials. Overall, The Handbook of Neuroprotection serves as a comprehensive review of neuroprotection based on knowledge of the molecular basis of disorders of the central nervous system. In-depth and authoritative, The Handbook of Neuroprotection, Second Edition features a compendium of vital knowledge aimed at providing researchers with an essential reference for this key neurological area of study.

Neuroprotection in Alzheimer’s Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer’s disease will pave the path to better disease management and novel therapeutics. Comprehensive reference detailing neuroprotection in Alzheimer’s Disease, with details on nerve cell protection and new advances in disease management Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development Edited by one of the leading researchers in Alzheimer’s Disease

Neuroprotection has been placed on a firm scientific basis during the past decade due to an improved understanding of the molecular basis of neurological diseases and the knowledge that treatment of neurological disorders should not be merely symptomatic but preventative against the progression of the underlying disease, as well as regenerative. The Handbook of Neuroprotection serves as a comprehensive review of neuroprotection based on knowledge of the molecular basis of neurological disorders. Neuroprotective effects of older, established drugs, as well as new drugs in development, are well documented in this detailed volume, featuring the most cutting-edge and innovative methods currently in use. In-depth and authoritative, The Handbook of Neuroprotection features a compendium of vital knowledge aimed at providing researchers with an essential reference for this key neurological area of study.

This book deals with basic and clinical aspects of monoamine oxidase (MAO) subtypes A and B highlighting its importance in neurological and psychiatric diseases. Consequently the therapeutic actions of MAO-A and -B inhibitors in Parkinson’s disease (PK) and depression are the focus of several chapters. As MAO is the basis of the development of the "oxidative stress hypothesis" of PD, several chapters are devoted to iron and iron-induced oxidative stress in various experimental studies and clinical conditions. Based on these findings, new compounds have been developed which not only block MAO, but are in addition, either inhibitors of acetylcholine esterase or have iron chelating properties. The aspect of "preclinical" and "clinical" neuro protection as well as MAO neuroprotection are additional topics covered in this book. MAO, iron and neuroprotection are seen in the framework of general anti Parkinson’s therapy with chapters on levodopa, dopaminergic receptor agonists and clinical issues.

Neuroscience Perspectives provides multidisciplinary reviews of topics in one of the most divers and rapidly advancing fields in the life sciences. Whether you are a new recruit to neuroscience, or an established expert, look to this series for 'one-stop' sources of the historical, physiological, pharmacological, biochemical, molecular biological, and therapeutic aspects of chosen research areas.

Neuroprotection is a strategy to prevent or delay the progression of chronic neurodegenerative diseases, acute neurological disorders, or even mental disorders. The major aim of this book is to focus on different approaches to achieve neuroprotection. In this book, there are chapters discussing imidazoline ligands and opioid ligands in Alzheimer's disease, the beneficial effects of adenosine A2A receptor antagonist, adrenergic receptor agonists and antagonists modulating microglial responses, and different approaches to achieve neuroprotection against aging-associated macular degeneration. This book will give insights to scientists in the field to stimulate their research, medical professionals to review their clinical practices, and others who would like to learn more about different neuroprotective approaches.

"CNS neuroprotection" was a common subject of papers, symposia, and reviews during the previous "decade of the brain. " Indeed, in recent years, experimental study of putative neuroprotective agents prompted clinical trials of numerous drug candidates in acute and chronic human neurodegenerative conditions. While the outcomes of these trials have not been as successful as initially hoped, these were early explorations, and the pipeline of relevant ideas continues to grow in strength and depth. We predict that early in this new millennium, crippling disorders such as stroke and Alzheimer's disease will be treated effectively by therapeutic neuroprotective strategies. This volume of the Handbook of Experimental Pharmacology titled eNS Neuroprotection provides a pharmacological perspective on currently promis ing neuroprotective approaches, and a clinical perspective on the challenges involved in establishing the efficacy of these approaches through appropriate clinical trials. Section I, "Mechanistic Approaches to CNS Neuroprotection," reviews major injury mechanisms that have formed the basis for many past and present clinical trials conducted around the world. Dr. KIM and colleagues, Washington University School of Medicine, review the status of blocking excitotoxicity as an approach to CNS neuroprotection. Dr. WANG, Pfizer Global Research and Development,Ann Arbor Laboratories, outlines evidence supporting a contri bution of apoptosis to pathological neuronal or glial cell loss. Drs. BECKER and HALLENBECK, University of Washington and the National Institute on Neuro logical Diseases and Stroke, respectively, argue that inhibiting inflammatory pathways in the brain can be neuroprotective. Dr.

This book examines current research into the role of neuronal death in cell signaling pathways, and its role in neurodegenerative diseases, such as Alzheimer's and Parkinson's. After introducing neurodegenerative, traumatic, and ishemic disorders, the authors cover in vitro and animal systems, and cellular and molecular mechanisms.